Cargando…
Analysis of efficacy, safety and prognostic factors of DAC-HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia
Hematopoietic stem cell transplantation (HSCT) is generally considered as the only effective treatment for children with relapsed/refractory (R/R) acute myeloid leukemia (AML). Achieving remission prior to HSCT affects the efficacy of the procedure and patient survival; therefore, induction therapy...
Autores principales: | Wang, Liang, Li, Chun, Xu, Fang, Cao, Fang, Zhang, Bo, Wang, Jing, Wang, Shen, Chen, Li, Li, Na, Liao, Chenglin, Liu, Hongjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591692/ https://www.ncbi.nlm.nih.gov/pubmed/34790353 http://dx.doi.org/10.3892/mco.2021.2431 |
Ejemplares similares
-
Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia
por: Lv, Wenxiu, et al.
Publicado: (2023) -
Treatment for Relapsed/Refractory Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2021) -
Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia
por: Vitkevičienė, Aida, et al.
Publicado: (2022) -
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022) -
The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML)
por: Yan-Fang, Tao, et al.
Publicado: (2013)